Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update

Systemic radioimmunotherapy (RIT) is arguably the most effective and least toxic anticancer treatment for non-Hodgkin lymphoma (NHL). In treatment-naive patients with indolent NHL, the efficacy of a single injection of RIT compares with that of multiple cycles of combination chemo-therapy. However, 20 years following the approval of the first CD20-targeting radioimmunocon-jugates 90Y-Ibritumomab-tiuxetan (Zevalin) and 131I-tositumomab (Bexxar), the number of patients referred for RIT in western countries has dramatically decreased. Notwithstanding this, the development of RIT has continued. Therapeutic targets other than CD20 have been identified, new vector molecules have been produced allowing for faster delivery of RIT to the target, and innovative radionuclides with favorable physical characteristics such as alpha emit-ters have been more widely available. In this article, we reviewed the current status of RIT in NHL, with particular focus on recent clinical and preclinical developments. Semin Nucl Med 53:413-425 (c) 2023 Elsevier Inc. All rights reserved.